In 2022, Domain Therapeutics, Université de Montréal (UdM) and Ono Pharmaceutical.,Ltd signed a collaboration agreement to discover novel small molecules targeting G-Protein Coupled Receptors in a metabolic disease area.
In this collaboration, the Domain’s proprietary technology platform, bioSens-All®, will be crucial to profile and select molecules as well as its expertise of GPCR medicinal chemistry and pharmacology. The three partners will design, profile and optimize innovative small molecules against a GPCR target. Ono will have worldwide exclusive rights to develop and commercialize products arising from the drug discovery collaboration. Domain and UdM will be eligible to upfront, research funding as well as research and development milestone and royalties.
In 2012, Domain and Ono Pharmaceutical Co., Ltd. (Osaka – Japan) signed a collaboration agreement focused on discovering small molecules targeting G-Protein Coupled Receptors (GPCRs).
Domain Therapeutics applied DTect-All™, its proprietary GPCR drug discovery platform and its expertise in GPCR medicinal chemistry and pharmacology to design and optimize small molecules into drug candidates having activity against GPCRs selected by Ono. Ono supported research activities and gained worldwide exclusive rights to develop and commercialize any pharmaceutical product arising out of the drug discovery collaboration. Under the terms of the agreement, Domain was eligible for undisclosed upfront, success-based milestones on the research, development milestones and royalties.